• Explore /
  • Poster
  • / A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498.

A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498.

Abstract Poster

Authors

null

John H. Sampson

Duke University Medical Center, Durham, NC

John H. Sampson , Antonio Marcilio Padula Omuro , Matthias Preusser , Michael Lim , Nicholas A. Butowski , Timothy Francis Cloughesy , Lewis C. Strauss , Robert Raymond Latek , Prashni Paliwal , Michael Weller , David A. Reardon

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Central Nervous System Tumors

Track

Central Nervous System Tumors

Sub Track

Central Nervous System Tumors

Clinical Trial Registration Number

NCT02617589

Citation

J Clin Oncol 34, 2016 (suppl; abstr TPS2079)

DOI

10.1200/JCO.2016.34.15_suppl.TPS2079

Abstract #

TPS2079

Poster Bd #

265b

Abstract Disclosures

Similar Posters

Poster

2020 ASCO Virtual Scientific Program

Phase III TRIDENT trial: Radiation and temozolomide +/- tumor treating fields in newly diagnosed glioblastoma.

Phase III TRIDENT trial: Radiation and temozolomide +/- tumor treating fields in newly diagnosed glioblastoma.

First Author: Wenyin Shi

First Author: Warren P. Mason

First Author: Patrick Roth

First Author: O. L. Chinot